Abstract:The International Society for Heart and Lung Transplantation (LTx) estimates that over 4600 lung transplants are currently performed worldwide each year. These LTx procedures represent less than 3% of all solid-organ transplants and the 5-year survival of recipients is generally poorer with 5 years post-transplantation survival rates of ~63% in Europe and ~54% in the United States. Development of chronic lung allograft dysfunction (CLAD), which causes irreversible lung damage, is the main contributor to long-term lung LTx survival. Phenotypically CLAD can exhibit clinical heterogeneity of with two phenotypes being described: bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS). BOS is generally characterized by the presence of obstructive pulmonary function, air trapping evident on CT scans, with histopathological evidence of obliterative bronchiolitis (OB). RAS patients present with restrictive pulmonary function, with persistent pleuro-parenchymal infiltrates evident on CT scans, and a type of scarring in the upper lobes of the lungs, termed pleuroparenchymal fibro-elastosis, evident on lung biopsies. While various risk factors have been identified, there is a paucity of genome-wide association studies performed to date for CLAD [1]. In this issue of EJHG , Brocard et al. describe the multicentric Genetic COhort in Lung Transplantation (GenCOLT) study, a powerful biobank resource to investigate the genetic determinants of long-term outcomes in lung transplantation [2]. GenCOLT has collected DNA and generated high-quality genome-wide genotyping and HLA Class I/II datasets for 387 LTx donor and recipient pairs from the overarching COLT study which comprised over 1400 lung transplant procedures across 12 French and Belgian LTx centers. GenCOLT donors were on average 45 years old, with 44% women, with the primary cause of death being stroke (54%). The average age of GenCOLT recipients at the time of LTx was 48 years old, 45% are women, with chronic obstructive pulmonary disease being the primary disease etiology (45%) precipitating the need for LTx. The average follow-up time in GenCOLT is 67 months between 2009 and 2018, with a 5-year survival average of 57.3% observed for the CLAD subgroup and 97.4% observed for the non-CLAD subgroup. The GenCOLT cohort was generally equivalent for clinical covariates, demographics, primary disease etiology and survival rates with the larger COLT study. Genetic variations can impact a wide range of processes, including immune responses, inflammation, and tissue repair, all of which play crucial roles in the development of CLAD and other complications [1]. By understanding the genetic basis of these processes, researchers can develop more accurate risk prediction models, identify novel therapeutic targets, and ultimately improve the long-term success of lung transplantation. This unique European resource combines extensive clinical data with high-quality genome-wide genetic information from both donors and recipients, for genome-wide association studies (GWAS) to be performed in CLAD and more widely in additional phenotypes and outcomes impacting lung transplantation.

Evolving trends in underlying etiologies for lung transplantation in Europe and outcomes

Lung transplantation in adults and children: putting lung function into perspective

A comparison of outcomes after lung transplantation between European and North American centers

GenCOLT: a multicenter European biobank for investigating genome-wide determinants of lung transplant outcomes

Lung Transplantation In China Between 2015 And 2018

Attitudes toward and preparedness for lung transplantation among individuals with cystic fibrosis in the era of highly effective modulators

Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system

Phenotyping CLAD after single lung transplant: Limits and prognostic assessment of the 2019 ISHLT classification system

Spectrum of chronic lung allograft dysfunction pathology in human lung transplantation

Lung transplantation for late-onset non-infectious chronic pulmonary complications of allogenic hematopoietic stem cell transplant

Reliability of diagnostic criteria for bronchiolitis obliterans syndrome after lung transplantation: a survey

Lung Transplantation for Bronchopulmonary Dysplasia

Outcomes of non-cystic fibrosis-related bronchiectasis post-lung transplantation

Impact of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplant Outcomes

A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor

Extended Recipient Criteria in Lung Transplantation: Impact of Pleural Abnormalities on Primary Graft Dysfunction

Lung Retransplantation Due to Chronic Lung Allograph Dysfunction: Results From a Spanish Transplant Unit

Outcomes of lung transplantation for pleuroparenchymal fibroelastosis: A French multicentric retrospective study

Lung transplantation in idiopathic pulmonary fibrosis

One-Year Mortality After Lung Transplantation: Experience of a Single French Center Between 2012 and 2021

A Retrospective Study of Lung Transplantation in Patients With Lymphangioleiomyomatosis: Challenges and Outcomes